Skip to content

Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction

Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07527494
Acronym
TWIN-SCD STEMI
Enrollment
1000
Registered
2026-04-14
Start date
2026-04-15
Completion date
2034-12-31
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden Cardiac Death, Myocardial Infarction

Keywords

Sudden cardiac death, Myocardial infarction, Prediction, Multiparametric model, Ventricular Arrhythmia

Brief summary

TWIN-SCD STEMI is a multicentric prospective, non-randomized pilot study designed to establish a multiparametric model for predicting life-threatening ventricular arrhythmias in patients experiencing their first myocardial infarction. The primary objective of the study is to develop an algorithm with superior predictive performance (sensitivity and specificity) compared to the currently used criterion for the implantation of a cardiac defibrillator, which is a left ventricular ejection fraction (LVEF) of less than 35%.

Detailed description

Sudden cardiac death (SCD) accounts for 10% of deaths in the general population, with 80% of these cases caused by malignant ventricular arrhythmias. These arrhythmias predominantly occur in individuals with cardiomyopathies, especially those with a history of myocardial infarction (MI). Currently, SCD prevention after a first MI relies on risk stratification based on myocardial contractility, specifically indicating prophylactic cardiac defibrillator implantation for patients with a left ventricular ejection fraction (LVEF) ≤ 35%. However, this approach is insufficient due to two main reasons: 1. Among patients with LVEF ≤ 35%, only a minority (2-5% per year) will experience arrhythmias and benefit from defibrillator implantation, while all face potential serious complications from the device. 2. Most SCD cases occur in patients with LVEF \> 35%. Although these patients have a lower individual arrhythmia risk (1-2% per year), they represent a substantially larger population at risk, with no stratification within this group. Emerging evidence suggests that additional parameters (biological markers, cardiac imaging, and electrophysiologic data) can better characterize the arrhythmogenic substrate in patients after their first MI, enabling improved identification of those at risk for arrhythmic SCD. The primary objective of this study is to develop a multiparametric model that outperforms the current criterion (LVEF \< 35%) for predicting the need for cardiac defibrillator implantation in patients presenting with a first myocardial infarction. Clinical data, biological data, imaging data of the scar using CT scan and MRI, and electrophysiological data from 12-lead ECG, 24-hour Holter ECG will be used to establish this multiparametric model. The model will be compared to the current criteria for predicting the occurrence of malignant ventricular arrhythmias (spontaneous during the one-year follow-up or induced by an electrophysiology study at 12 months and 24 months) in this cohort.

Interventions

Invasive cardiac electrophysiology (EP) study

Cardiac CT scan with contrast enhancement

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Prospective multicenter cohort study, non-randomized, with intervention

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* History of ST-segment elevation myocardial infarction (STEMI) in the last 6 months * Signed informed consent * Affiliated to or beneficiary of a health insurance

Exclusion criteria

* Renal failure (Creatinine clearance \<30 mL/min), or a systemic illness likely to limit survival to \<1 year * Women who are pregnant, lactating, or who are planning to become pregnant within 2 years following her inclusion * Unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent * Participant under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of sudden cardiac death or sustained ventricular arrhythmiaFrom enrollment to the end of the 60-months follow-upEvent defined by occurrence of sudden cardiac death or appriopriate ICD shock delivery or sustained ventricular arrhythmia (lasting more than 30 seconds)

Secondary

MeasureTime frameDescription
Occurrence of syncope at M60At month 60 after enrillmentOccurrence of syncope at M60
Occurrence of non-sustained ventricular arrhythmias at M60At month 60 after inclusionOccurrence of non-sustained ventricular arrhythmias at M60

Countries

France

Contacts

CONTACTEdouard GERBAUD, MD
edouard.gerbaud@chu-bordeaux.fr+33(0)524549188
CONTACTValérie BOILET
valerie.boilet@chu-bordeaux.fr+33(0)524549366
STUDY_DIRECTORJosselin DUCHATEAU, MD

University Hospital, Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026